CRYSTAL ROGER 4

What Happened

• Crystal Roger, a director of Definium Therapeutics (DFTX), received equity awards on 2026-06-11 consisting of 4,666 restricted stock units (RSUs) and a 19,188-share derivative award, both reported at $0 per share. Total awarded = 23,854 shares (no cash changed hands at grant). The Form 4 was filed on 2026-06-15.

Key Details

• Transaction date: 2026-06-11; reported on Form 4: 2026-06-15 (timely filing — within two business days).
• Price: $0.00 per share (award/grant).
• Shares owned after transaction: not specified in the data provided.
• Footnotes of the filing:
  • F1: The 4,666 shares are RSUs; each RSU converts to one common share and vests 1/12th monthly, with a special annual-meeting acceleration clause if applicable.
  • F2: The derivative award follows a monthly 1/12 vesting schedule similar to a stock option, with the same annual-meeting acceleration clause (per the filing).
• Transaction code: A (award/grant); the 19,188-item is reported as a derivative.

Context

• These were equity awards (not open-market purchases or sales). RSUs and derivative awards typically vest over time and do not represent immediately tradable shares unless vested; they do not indicate an immediate buy or sell decision. No exercise or sale was reported in this filing.